Powerful Medical Receives €40 Million IPCEI Grant — read the full story

Powerful Medical
11. November 2024
3 min to read

Female Patients with Occlusive Myocardial Infarction without ST Elevation Experience Longer Delays in Receiving Emergent Reperfusion

Female Patients with Occlusive Myocardial Infarction without ST Elevation Experience Longer Delays in Receiving Emergent Reperfusion

Overview

Up to a third of high-risk heart attacks go unrecognized by traditional ECG diagnostic criteria, causing dangerous delays—an effect even more pronounced in women, who remain understudied in this context. This analysis reveals a 4.4-hour treatment delay for initially misclassified female patients compared to males, highlighting the urgent need for modern, unbiased diagnostic solutions.

Published In: Circulation (AHA Journals) – presented at the American Heart Association (AHA) 2024 Scientific Sessions
Presented Date: November 11, 2024

Background

Sex disparities in symptom presentation are well-documented in female patients with Acute Coronary Syndrome (ACS). Moreover, nearly half of the patients with acutely occlusive myocardial infarction (OMI) do not meet the STEMI criteria at admission, leading to delays in receiving emergent reperfusion. This delay may be more pronounced in female OMI patients without ST-elevation (NSTEMI-OMI), potentially due to differences in symptom presentation and recognition.

Purpose

To investigate disparities in delays from admission ECG to percutaneous coronary intervention (PCI) between male and female patients with acute OMI stratified according to the presence of STEMI criteria.

Methods

Electrocardiograms (ECGs), laboratory and coronary angiography (CAG) data were sourced from a total of 623 consecutive OMI patients from five international cohorts from 2012 to 2023. The final diagnosis of OMI was adjudicated by two expert physicians based on all available data. Patients were stratified into STEMI-OMI and NSTEMI-OMI based on their initial admission ECG and time-to-PCI: <2hrs vs. >2hrs, respectively. Each cohort was further subdivided based on sex (male vs. female).

Results

A total of 314 STEMI-OMI patients (24% female) and 309 NSTEMI-OMI (30% female) were included in the analysis. Median ECG-to-balloon (E2B) time between STEMI-OMI and NSTEMI-OMI patients was 48 minutes and 17.1 hours, respectively (p<0.001). Female STEMI-OMI patients had an E2B of 47.0 minutes (95% CI: 30-78), compared to 50.6 minutes (95% CI: 30-72) for male patients, respectively, and did not differ significantly (p=0.85) (Fig 1A). In NSTEMI-OMI, female patients had a significantly longer median E2B time of 20.1 hours (95% CI: 10.2-48.2) as compared to 15.7 hours (95% CI: 5.6-28.0) (p=0.002) in male patients (Fig 1B).

Conclusion

The present international multi-centric validation of consecutive patients with acute coronary occlusion reveals a significant sex disparity in NSTEMI-OMI patients, with female patients experiencing a 4.4-hour delay to reperfusion compared to males. These findings highlight the need for unbiased diagnostic strategies to address sex differences in ACS presentation.


Authors: Timea Kisova, MD, BSc, Robert Herman, MD, Anthony Demolder, MD, MSc, PhD, Jakub Bahyl, Mgr, Hana Hybasek Dzurikova, MRCVS, PGCert MEd, Stephen Smith, MD, Harvey Meyers, MD, Mark Hellerman, MD, Rinaldo Lauwers, MD, David Pletnickx, MD, Dan Schelfaut, MD, Fadi El Ters, MD, Alain Tanios, MD, Fabrizio Ricci, MD, PhD, MSc, Davide Rossi, MD, Jozef Bartunek, Prof.,MUDr.,PhD, and Emanuele Barbato, Prof.,MD

Author-Logo_PM
Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.

About PMcardio

PMcardio is a CE-certified AI that reads ECGs and offers a complex assessment of 49 cardiac conditions. Clinically validated in 15+ studies and trusted by over 100,000 clinicians, it delivers rapid, expert‑level interpretations, empowering emergency physicians, GPs, nurses, paramedics, and cardiologists to act with confidence at the point of care. Available for Individuals and Organizations.

About Powerful Medical

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

Share this article

Relevant Publications

Artificial intelligence-enhanced ECG detection of acute coronary occlusion in chest pain patients with ST-elevation in lead aVR – A direct comparison to conventional ECG criteria

In a single‑centre retrospective study of 145 consecutive emergency‑department patients whose first ECG showed ≥1 mm ST‑elevation in lead aVR, investigators compared conventional electrocardiographic rules with a deep‑learning classifier (PMcardio “Queen of Hearts”) for recognising an acute coronary occlusion (ACO). Angiography and biomarker adjudication proved ACO in 19 patients (13 %). At an optimised probability threshold, the AI system achieved an area‑under‑the‑ROC curve of 0.918, detected 63 % of occlusions, and—crucially—generated no false‑positive calls in the 54‑patient rule‑out subgroup. By contrast, classic STEMI millimetre criteria identified only one in four occlusions and would have prompted between four and fourteen unnecessary emergency catheterisations.

AI-enhanced recognition of occlusions in acute coronary syndrome (AERO-ACS): a retrospective study

In a one‑year, single‑centre cohort of 217 cath‑lab patients (72 STEMI, 145 NSTEMI), the AERO‑ACS study tested PMcardio’s AI ECG against traditional ST‑elevation rules for detecting angiographic occlusion‑MI. The algorithm matched STEMI sensitivity (86.5 % vs 83.3 %) while raising specificity to 82.2 % (vs 66.0 %), achieved 100 % sensitivity in STEMI cases, and flagged occlusions linked to a 12‑fold higher in‑hospital mortality risk—suggesting more accurate triage with fewer unnecessary activations.

Join over 100,000 healthcare professionals who are already taking advantage of AI